Biosensors   

Is Biosensors a good buy?

Buy or sell also must have juice, otherwise you will still lose.  " Juice" is borrowed from sifu iPunter.

 

too coarse.

should be " buy on rumours, when volume pick up" , " sell on news almost release"  

trust me though i primarily on shorting but i have 20 yrs of longing experience.......cheers 

aleoleo      ( Date: 30-May-2012 09:03) Posted: buy on rumours sell on news ...

 

i think can consider to short..

aleoleo      ( Date: 30-May-2012 09:03) Posted: buy on rumours sell on news ...

 

buy on rumours sell on news ...

 

CIMB  Analysis    By Gary NG

Biosensors Int'l			4QFY12RESULTSNOTE
BIG SP/ BIOS.SI	Current	S$1.29		SHORTTERM(3 MTH)	LONG TERM
Market Cap	AvgDailyTurnover	Free Float		Target	S$1.82
US$1,732m	US$8.11m	42%		Previous Target	S$1.98
S$2,212m	S$10.19m	1,721m shares		Up/downside	41.6%

Not a bad romance

Resultsexceedmanagement’s guidance. After investors’ initial overreaction toprice-reduction fears in China, bargain valuationshaveemerged. We areoptimistic on product penetration in key Asia-Pacific markets.

FY12 core meets 98% of Street and 104% of our expectations. We lower our margin assumptions conservatively on easing ASPs and reduced FY13-14 EPS, and our SOP target accordingly. Retain Outperform on market leadership and product superiority.

FY12 recap

4Q12 revenue of S$88.2m (+98.2% yoy) was fired by strong growth in stent sales, boosted by the consolidation of JWMS. Licensing and royalty revenue grew to US$22.8m (+378.3% yoy), led by Nobori DES sales in Japan under Terumo. Gross margins improved sequentially to 82.0% on the back of lower JWMS consolidation costs and cost control. Demand in EMEA and Asia Pacific remains strong. In China, management has yet to discern any destocking in anticipation of weaker prices, as claimed by the Chinese media.

FY13 guidance

Management expects profitability to improve by 20-30% yoy in FY13. While scope for growth in licensing revenue is limited, sales volume in EMEA and Asia Pacific continues to gain traction, with greater marketing efforts and penetration. This should overwhelm easing ASPs. Management is still sanguine on BIG’s product superiority which should bestow higher spectrum pricing power.

Catalysts

SFDA approval for the launch of BioMatrix will be paramount for blunting the impact of any mandated price reductions (in China and Japan

 

Traders who appreciate values are already extinct, so you cannot find them. Few that are left cannot do much to make market rise to its worth.

Only manipulators are around and they are very strongly backed by authoritative people, I think. So no chance for the man in the street here in sgmart. Smart people no longer play Singapore. They play China and Europe. Dummies are left here.

Soon brokerage firms will lose business and start to eat their clients to survive. Be careful.

 

I thought 4th quarter results must have been very bad for the sell down but its actually very good.  The fund which sold down BIG  must have done so to cover its European loss. At current price its good to collect for investors.  If it doesn't go above 1.50 the Chairman will not get his honey.  All  BIG needs is another fund to come in or China approval or CE mark news. 

yiming2000      ( Date: 29-May-2012 22:32) Posted: You are damn right about the Singapore market. Biosensors' 4Q results is as stunning as Apple's rocket-like financial performance when Steve Jobs was alive. Yet, no one is rushing in to buy this stock. Either the Singapore trader is smart and know that Biosensors is lying about it's performance or he is kiasu and kiasi. I went in at $1.50 with 20 lots and still losing $4000. I should average down another 20 lots but someone here said that it would be committing suicide a second time. He made me kiasi. tea444u      ( Date: 29-May-2012 21:35) Posted: hmm not to sund like sour grapes but could there be a sell on news for this??/somehow the singapore market really donnoo how to   value good stocks like this.... penny stocks on watch lists get more attention...pui

 

You are damn right about the Singapore market. Biosensors' 4Q results is as stunning as Apple's rocket-like financial performance when Steve Jobs was alive. Yet, no one is rushing in to buy this stock. Either the Singapore trader is smart and know that Biosensors is lying about it's performance or he is kiasu and kiasi.

I went in at $1.50 with 20 lots and still losing $4000. I should average down another 20 lots but someone here said that it would be committing suicide a second time. He made me kiasi.

tea444u      ( Date: 29-May-2012 21:35) Posted: hmm not to sund like sour grapes but could there be a sell on news for this??/somehow the singapore market really donnoo how to   value good stocks like this.... penny stocks on watch lists get more attention...pui

 

hmm not to sund like sour grapes but could there be a sell on news for this??/somehow the singapore market really donnoo how to   value good stocks like this.... penny stocks on watch lists get more attention...pui

 

I am a long term value investor and I have holdings all over the world.    I look toward Mr. Buffet as a model and so far he has not steered me wrong.  Compared with other medical device companies in America and Europe BIG has done a spectacular job.  The new management seems to under promise and over perform.  It is to be commended on delivering the potential this counter has had for many years but has failed to realize.  If this stock were listed in HK or NAS it would have a price  over $2.00 based on stellar growth delivered and potential growth to be delivered. 

I am puzzled at the trader mentality that seems to control this counter and think this too shall pass.  I am looking for a short term target of 1.60 - 1.80 provided that foreign investment funds recognize the counter's value.  Based on new investors Lenovov success, I am betting they will.

 

Excluding CE approval for BioFreedom, and SFDA approval for Biomatrix, the  current fair value should be $1.53. One year tagt price assuming a 20-25% growth would be  1..83-90. Buf if factor in imminent CE approval for BioFreedom which  should  come before large scale trial starts around end of the year, we can expect price to revisit the recent peak of 1.68 in coming months.

Tomorrow price should be around the 1.33-1.36 range.

 

I don`t think so. The result exceeded the top end of expectation and next year`s growth guidance of 30% is realistic and fair.  The company  is holding a large cash holding and not giving out any dividend is a clear signal of imminent acquisition coming soon. I am happy with the result. 

sylvincent      ( Date: 29-May-2012 17:50) Posted: The results are within expectations. The projected growth for the next year isn't as good though. Still, this doesn't explain the recent sell down.

 

This is all about stock pyschology......unless you are new to trading! :-) 

sylvincent      ( Date: 29-May-2012 17:50) Posted: The results are within expectations. The projected growth for the next year isn't as good though. Still, this doesn't explain the recent sell down.

 

Conference

Guidance of growth of 20-30% excludes approval of SFDA for Bipmarix and CE for BioFreedom,

Growth guidance for 2013  of 20-30% stent based largely on sales growth  rather than licensing growth  (Terumo's Nobori   growth will plateau) also guidance build in little growth from China due to pricing of new tendering system

Will acctively seek new Products acquisitions -focusing on platform rather than products- however new products  not priced in, but on the look out for.growth

Cost of Trial for BioFreedom  priced in for the Growth guidance. Trial of 16000 to be purchased from Biomatrix (i.e. not free), but Biosensors will contribute to the study.

CE approval for BioFreedom should be coming  in near future. CE approval not dependant on the new massive trial but earlier trial of which data has been submitted and of which the trial  is still on going

 

Key issue for price3 movmnt tokmorrow will depend on revelations and clarifiactions tonight at conference all. FOr isntance need to know the following

a) SFDA approval for Biomatrid

b) CE approval for BioFreedom

c) New Acquistions??

d) Imapct of Euro on BIG's earnings and prices of stents

 

 

The results are within expectations. The projected growth for the next year isn't as good though.

Still, this doesn't explain the recent sell down. 

 

Why should it plunge? Quite the contrary.

 

Results out. So will price plunge????

 

 

Sounds like there are no investors here. All gamblers. I have to play against you guys.

 

low vol to sell down yesterday .... low vol to catch up back today ....

really catch no balls. ....